{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:52:51Z","timestamp":1793641971224,"version":"4.5.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lfs.2024.122989","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T02:32:31Z","timestamp":1724725951000},"page":"122989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Recent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma"],"prefix":"10.1016","volume":"356","author":[{"given":"Fatemeh Sadat","family":"Shafiei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Abroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2024.122989_bb0005","doi-asserted-by":"crossref","unstructured":"Dehghanifard, A., Kaviani, S., Abroun, S., Mehdizadeh, M., Saiedi, S., Maali, A., Ghaffari, S., & Azad, M. (2018, 2018\/05\/01\/). Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways. Clin. Lymphoma Myeloma Leuk., 18(5), 311\u2013320. doi:https:\/\/doi.org\/10.1016\/j.clml.2018.03.007.","DOI":"10.1016\/j.clml.2018.03.007"},{"issue":"3","key":"10.1016\/j.lfs.2024.122989_bb0010","first-page":"266","article-title":"Osteogenic inhibition in multiple myeloma","volume":"15","author":"Habibi","year":"2013","journal-title":"Cell J."},{"issue":"2","key":"10.1016\/j.lfs.2024.122989_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.146","article-title":"Pathogenesis and treatment of multiple myeloma","volume":"3","author":"Yang","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.lfs.2024.122989_bb0020","doi-asserted-by":"crossref","unstructured":"Omstead, D. T., Mejia, F., Sjoerdsma, J., Kim, B., Shin, J., Khan, S., Wu, J., Kiziltepe, T., Littlepage, L. E., & Bilgicer, B. (2020, 2020\/11\/02). In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma. J. Hematol. Oncol., 13(1), 145. doi:https:\/\/doi.org\/10.1186\/s13045-020-00965-4.","DOI":"10.1186\/s13045-020-00965-4"},{"issue":"25","key":"10.1016\/j.lfs.2024.122989_bb0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215711120","article-title":"In vivo bone marrow microenvironment siRNA delivery using lipid\u2013polymer nanoparticles for multiple myeloma therapy","volume":"120","author":"Guimar\u00e3es","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"17","key":"10.1016\/j.lfs.2024.122989_bb0030","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.3390\/cancers13174320","article-title":"Choosing the right therapy for patients with relapsed\/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors","volume":"13","author":"Gengenbach","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.lfs.2024.122989_bb0035","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.3390\/ijms22094462","article-title":"The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma","volume":"22","author":"Giannakoulas","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0609.2011.01700.x","article-title":"Genetic variations in multiple myeloma I: effect on risk of multiple myeloma","volume":"88","author":"Vangsted","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122989_bb0045","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.4081\/hr.2020.9054","article-title":"The molecular pathogenesis of multiple myeloma","volume":"12","author":"Bolli","year":"2020","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.lfs.2024.122989_bb0050","doi-asserted-by":"crossref","unstructured":"Clarke, S. E., Fuller, K. A., & Erber, W. N. (2024, 2024\/03\/01\/). Chromosomal defects in multiple myeloma. Blood Rev., 64, 101168. doi:https:\/\/doi.org\/10.1016\/j.blre.2024.101168.","DOI":"10.1016\/j.blre.2024.101168"},{"key":"10.1016\/j.lfs.2024.122989_bb0055","doi-asserted-by":"crossref","unstructured":"Hoang, P. H., Cornish, A. J., Sherborne, A. L., Chubb, D., Kimber, S., Jackson, G., Morgan, G. J., Cook, G., Kinnersley, B., Kaiser, M., & Houlston, R. S. (2020, 2020\/10\/14). An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood Cancer J., 10(10), 101. doi:https:\/\/doi.org\/10.1038\/s41408-020-00367-2.","DOI":"10.1038\/s41408-020-00367-2"},{"issue":"8","key":"10.1016\/j.lfs.2024.122989_bb0060","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/cas.13697","article-title":"Exosomes in cancer development and clinical applications","volume":"109","author":"Tai","year":"2018","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0065","first-page":"373","article-title":"Multiple myeloma: diagnosis and treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am. Fam. Physician"},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0070","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000502","article-title":"A journey through myeloma evolution: from the normal plasma cell to disease complexity","volume":"4","author":"Da Vi\u00e0","year":"2020","journal-title":"Hemasphere"},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0075","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"van de Donk","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lfs.2024.122989_bb0080","first-page":"421","article-title":"Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression. World","volume":"15","author":"Garc\u00eda-S\u00e1nchez","year":"2023","journal-title":"J. Stem Cells"},{"issue":"3","key":"10.1016\/j.lfs.2024.122989_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282841","article-title":"Calprotectin as new potential clinical marker for multiple myeloma","volume":"18","author":"Khosravi","year":"2023","journal-title":"PLoS One"},{"issue":"S1","key":"10.1016\/j.lfs.2024.122989_bb0090","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.lfs.2024.122989_bb0095","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/jcm10091841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies\u2014current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.lfs.2024.122989_bb0100","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.lfs.2024.122989_bb0105","doi-asserted-by":"crossref","unstructured":"McKenzie, F., Gazz\u00e9, G., Hewitt, J., Kolm, K., Pollock, D., Rowland, S., & Crosbie, T. (2022, 2022-December-08). Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews [perspective]. Frontiers in Oncology, 12. doi:https:\/\/doi.org\/10.3389\/fonc.2022.1061417.","DOI":"10.3389\/fonc.2022.1061417"},{"issue":"4","key":"10.1016\/j.lfs.2024.122989_bb0110","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cancers13040863","article-title":"Role of stem cell transplantation in multiple myeloma","volume":"13","author":"Devarakonda","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2024.122989_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted therapy with immunoconjugates for multiple myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122989_bb0120","first-page":"503","article-title":"AntagomiR-19a induced better responsiveness to bortezomib in myeloma cell lines","volume":"23","author":"Kazemi","year":"2021","journal-title":"Cell J."},{"key":"10.1016\/j.lfs.2024.122989_bb0125","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients\u2019 selection and perspective","volume":"12","author":"Trudel","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"19","key":"10.1016\/j.lfs.2024.122989_bb0130","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.3390\/cancers13194978","article-title":"Management of adverse events and supportive therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Pozzi","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1526","article-title":"Nanotherapeutics for multiple myeloma","volume":"10","author":"Zheleznyak","year":"2018","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lfs.2024.122989_bb0150","doi-asserted-by":"crossref","unstructured":"Heshmati Aghda, N., Dabbaghianamiri, M., Tunnell, J. W., & Betancourt, T. (2022, 2022\/06\/10\/). Design of smart nanomedicines for effective cancer treatment. Int. J. Pharm., 621, 121791. doi:https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121791.","DOI":"10.1016\/j.ijpharm.2022.121791"},{"issue":"13","key":"10.1016\/j.lfs.2024.122989_bb0155","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.3390\/molecules28135145","article-title":"Cancer nanomedicine: emerging strategies and therapeutic potentials","volume":"28","author":"Xu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2024.122989_bb0160","doi-asserted-by":"crossref","unstructured":"Metselaar, J., Lammers, T., Boquoi, A., Fenk, R., Testaquadra, F., Schemionek, M., Kiessling, F., Isfort, S., Wilop, S., & Crysandt, M. (2023, 2023\/04\/01). A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma. Drug Deliv. Transl. Res., 13(4), 915\u2013923. doi:https:\/\/doi.org\/10.1007\/s13346-022-01268-6.","DOI":"10.1007\/s13346-022-01268-6"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2024.122989_bb0170","doi-asserted-by":"crossref","unstructured":"Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., Nwadike, U. G., Ogbodo, J. O., Umeh, B. U., Ossai, E. C., & Nwanguma, B. C. (2023, 2023\/06\/01\/). Advances in drug delivery systems, challenges and future directions. Heliyon, 9(6), e17488. doi:https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17488.","DOI":"10.1016\/j.heliyon.2023.e17488"},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0175","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomedicine"},{"issue":"14","key":"10.1016\/j.lfs.2024.122989_bb0180","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"issue":"13","key":"10.1016\/j.lfs.2024.122989_bb0185","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","article-title":"Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles","volume":"31","author":"He","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2024.122989_bb0190","doi-asserted-by":"crossref","unstructured":"Abbasi, R., Shineh, G., Mobaraki, M., Doughty, S., & Tayebi, L. (2023, 2023\/02\/27). Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. J. Nanopart. Res., 25(3), 43. doi:https:\/\/doi.org\/10.1007\/s11051-023-05690-w.","DOI":"10.1007\/s11051-023-05690-w"},{"issue":"8","key":"10.1016\/j.lfs.2024.122989_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082150","article-title":"Biopolymer-based nanosystems: potential novel carriers for kidney drug delivery","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2024.122989_bb0200","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2016.11.014","article-title":"Tumor-targeted nanomedicines for cancer theranostics","volume":"115","author":"Arranja","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"13","key":"10.1016\/j.lfs.2024.122989_bb0210","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3390\/polym14132601","article-title":"Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect","volume":"14","author":"Ejigah","year":"2022","journal-title":"Polymers"},{"issue":"4","key":"10.1016\/j.lfs.2024.122989_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/jfb13040196","article-title":"Overview of physicochemical properties of nanoparticles as drug carriers for targeted cancer therapy","volume":"13","author":"Yagublu","year":"2022","journal-title":"J Funct Biomater"},{"key":"10.1016\/j.lfs.2024.122989_bb0220","doi-asserted-by":"crossref","unstructured":"Honary, S., & Zahir, F. (2013, 05\/09). Effect of zeta potential on the properties of nano-drug delivery systems - a review (part 1). Trop. J. Pharm. Res., 12. doi:https:\/\/doi.org\/10.4314\/tjpr.v12i2.19.","DOI":"10.4314\/tjpr.v12i2.19"},{"key":"10.1016\/j.lfs.2024.122989_bb0225","doi-asserted-by":"crossref","unstructured":"Lestari, W. A., Wahyuningsih, S., Gomez-Ruiz, S., & Wibowo, F. R. (2022, 2022\/03\/01). Drug loading ability and release study of various size small mesoporous silica nanoparticle as drug carrier. J. Phys. Conf. Ser., 2190(1), 012032. doi:https:\/\/doi.org\/10.1088\/1742-6596\/2190\/1\/012032.","DOI":"10.1088\/1742-6596\/2190\/1\/012032"},{"key":"10.1016\/j.lfs.2024.122989_bb0230","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bmt.2023.09.001","article-title":"Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment","volume":"5","author":"Elumalai","year":"2024","journal-title":"Biomed. Tech."},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122904","article-title":"Nanomedicine penetration to tumor: challenges, and advanced strategies to tackle this issue","volume":"14","author":"Munir","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0240","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/pharmaceutics14122708","article-title":"Design of nanoparticles in cancer therapy based on tumor microenvironment properties","volume":"14","author":"Mahdavi Firouzabadi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2024.122989_bb0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2024.122989_bb0250","doi-asserted-by":"crossref","unstructured":"Kizhakkanoodan, K. S., Rallapalli, Y., Praveena, J., Acharya, S., & Guru, B. R. (2023, 2023\/12\/12). Cancer nanomedicine: emergence, expansion, and expectations. SN Appl. Sci., 5(12), 385. doi:https:\/\/doi.org\/10.1007\/s42452-023-05593-4.","DOI":"10.1007\/s42452-023-05593-4"},{"key":"10.1016\/j.lfs.2024.122989_bb0255","series-title":"Encyclopedia of Biomedical Engineering","first-page":"345","article-title":"Gene delivery and clinical applications","author":"Morshed","year":"2019"},{"issue":"10","key":"10.1016\/j.lfs.2024.122989_bb0260","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lfs.2024.122989_bb0265","doi-asserted-by":"crossref","unstructured":"Detappe, A., Bustoros, M., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018, 2018\/06\/01\/). Advancements in nanomedicine for multiple myeloma. Trends Mol. Med., 24(6), 560\u2013574. doi:https:\/\/doi.org\/10.1016\/j.molmed.2018.04.005.","DOI":"10.1016\/j.molmed.2018.04.005"},{"key":"10.1016\/j.lfs.2024.122989_bb0270","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to improve the EPR effect: a mechanistic perspective and clinical translation","volume":"345","author":"Ikeda-Imafuku","year":"2022","journal-title":"J. Control. Release"},{"issue":"26","key":"10.1016\/j.lfs.2024.122989_bb0275","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.7150\/thno.37198","article-title":"Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment [review]","volume":"9","author":"Park","year":"2019","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0280","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/jpm11060571","article-title":"Recent advances in tumor targeting via EPR effect for cancer treatment","volume":"11","author":"Subhan","year":"2021","journal-title":"Journal of Personalized Medicine"},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0285","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/cancers14122868","article-title":"An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment","volume":"14","author":"Sharifi","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.lfs.2024.122989_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25092193","article-title":"Therapeutic nanoparticles and their targeted delivery applications","volume":"25","author":"Yetisgin","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2024.122989_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109712","article-title":"Zinc oxide nanoparticles induce human multiple myeloma cell death via reactive oxygen species and Cyt-C\/Apaf-1\/Caspase-9\/Caspase-3 signaling pathway in vitro","volume":"122","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0300","article-title":"Applications of surface modification technologies in nanomedicine for Deep Tumor Penetration","volume":"8","author":"Li","year":"2020","journal-title":"Adv Sci (Weinh)"},{"issue":"23","key":"10.1016\/j.lfs.2024.122989_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236056","article-title":"Overcoming hurdles in nanoparticle clinical translation: the influence of experimental design and surface modification","volume":"20","author":"Shreffler","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2024.122989_bb0310","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/cancers16020447","article-title":"Antibody\u2013drug conjugates: the dynamic evolution from conventional to next-generation constructs","volume":"16","author":"Metrangolo","year":"2024","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.lfs.2024.122989_bb0315","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1039\/D2RA07863E","article-title":"Cancer nanomedicine: a review of nano-therapeutics and challenges ahead","volume":"13","author":"Nirmala","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.lfs.2024.122989_bb0320","doi-asserted-by":"crossref","unstructured":"Tian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., Nice, E. C., Xie, N., Huang, C., & Shen, Z. (2022, 2022\/09\/12). Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J. Hematol. Oncol., 15(1), 132. doi:https:\/\/doi.org\/10.1186\/s13045-022-01320-5.","DOI":"10.1186\/s13045-022-01320-5"},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122561","article-title":"Aptamers as smart ligands for targeted drug delivery in cancer therapy","volume":"14","author":"Wei","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.lfs.2024.122989_bb0330","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/cancers11050640","article-title":"Active targeting strategies using biological ligands for nanoparticle drug delivery systems","volume":"11","author":"Yoo","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.lfs.2024.122989_bb0335","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: biological basis, clinical use and new drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0340","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-017-1990-2","article-title":"The multi-faceted potential of CD38 antibody targeting in multiple myeloma","volume":"66","author":"Shallis","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.lfs.2024.122989_bb0345","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/pharmaceutics15092233","article-title":"Recent advances in targeted drug delivery strategy for enhancing oncotherapy","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0350","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1080\/10717544.2020.1831103","article-title":"Cell-mediated targeting drugs delivery systems","volume":"27","author":"Yu","year":"2020","journal-title":"Drug Deliv."},{"issue":"2\u20134","key":"10.1016\/j.lfs.2024.122989_bb0355","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1515\/ejnm-2012-0010","article-title":"Limitations and niches of the active targeting approach for nanoparticle drug delivery","volume":"4","author":"Chen","year":"2012","journal-title":"European Journal of Nanomedicine"},{"issue":"9","key":"10.1016\/j.lfs.2024.122989_bb0360","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/pr9091527","article-title":"Challenges towards targeted drug delivery in cancer nanomedicines","volume":"9","author":"Hafeez","year":"2021","journal-title":"Processes"},{"issue":"10","key":"10.1016\/j.lfs.2024.122989_bb0365","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1039\/D2BM00315E","article-title":"Nanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancer","volume":"10","author":"Shaw","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.lfs.2024.122989_bb0370","doi-asserted-by":"crossref","unstructured":"Khan, A. A., Allemailem, K. S., Almatroudi, A., Almatroodi, S. A., Alsahli, M. A., & Rahmani, A. H. (2021, 2021\/02\/01\/). Novel strategies of third level (organelle-specific) drug targeting: an innovative approach of modern therapeutics. Journal of Drug Delivery Science and Technology, 61, 102315. doi:https:\/\/doi.org\/10.1016\/j.jddst.2020.102315.","DOI":"10.1016\/j.jddst.2020.102315"},{"key":"10.1016\/j.lfs.2024.122989_bb0375","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.sajce.2023.08.009","article-title":"An overview of nanoparticles in drug delivery: properties and applications","volume":"46","author":"Hsu","year":"2023","journal-title":"South African Journal of Chemical Engineering"},{"key":"10.1016\/j.lfs.2024.122989_bb0380","doi-asserted-by":"crossref","unstructured":"Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021, 2021\/09\/01). The evolution of commercial drug delivery technologies. Nature Biomed. Eng., 5(9), 951\u2013967. doi:https:\/\/doi.org\/10.1038\/s41551-021-00698-w.","DOI":"10.1038\/s41551-021-00698-w"},{"key":"10.1016\/j.lfs.2024.122989_bb0385","series-title":"Stimuli-responsive Nanocarriers","first-page":"1","article-title":"Chapter 1 - an overview of stimuli-responsive nanocarriers: State of the art","author":"Kumar","year":"2022"},{"issue":"10","key":"10.1016\/j.lfs.2024.122989_bb0390","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.7150\/thno.38069","article-title":"Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics","volume":"10","author":"Mi","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.lfs.2024.122989_bb0395","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2010.02.024","article-title":"Tumoral acidic pH-responsive MPEG-poly (\u03b2-amino ester) polymeric micelles for cancer targeting therapy","volume":"144","author":"Min","year":"2010","journal-title":"J. Control. Release"},{"issue":"30","key":"10.1016\/j.lfs.2024.122989_bb0400","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1016\/j.biomaterials.2010.07.005","article-title":"Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin","volume":"31","author":"Talelli","year":"2010","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0405","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.biomaterials.2012.12.031","article-title":"A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy","volume":"34","author":"Yuba","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2024.122989_bb0410","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ces.2014.08.046","article-title":"Controlled drug release from pharmaceutical nanocarriers","volume":"125","author":"Lee","year":"2015","journal-title":"Chem. Eng. Sci."},{"issue":"15","key":"10.1016\/j.lfs.2024.122989_bb0415","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1016\/j.biomaterials.2011.01.075","article-title":"The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors","volume":"32","author":"Li","year":"2011","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.lfs.2024.122989_bb0420","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1039\/D0NJ05169A","article-title":"Stimulus-responsive nanocarriers for targeted drug delivery","volume":"45","author":"Fang","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.lfs.2024.122989_bb0425","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Kuang, G., Li, W., Wang, J., Ren, H., & Zhao, Y. (2023a, 2023\/02\/08). Stimuli-responsive gene delivery nanocarriers for cancer therapy. Nano-Micro Letters, 15(1), 44. doi:https:\/\/doi.org\/10.1007\/s40820-023-01018-4.","DOI":"10.1007\/s40820-023-01018-4"},{"key":"10.1016\/j.lfs.2024.122989_bb0430","doi-asserted-by":"crossref","unstructured":"Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023, 2023\/11\/03). Smart nanoparticles for cancer therapy. Signal Transduction and Targeted Therapy, 8(1), 418. doi:https:\/\/doi.org\/10.1038\/s41392-023-01642-x.","DOI":"10.1038\/s41392-023-01642-x"},{"issue":"5","key":"10.1016\/j.lfs.2024.122989_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.lfs.2024.122989_bb0440","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"46","key":"10.1016\/j.lfs.2024.122989_bb0445","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0450","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","article-title":"Ligand-targeted liposome design: challenges and fundamental considerations","volume":"32","author":"Noble","year":"2014","journal-title":"Trends Biotechnol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122989_bb0455","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/10408398.2011.559558","article-title":"Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity","volume":"51","author":"McClements","year":"2011","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.lfs.2024.122989_bb0460","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejps.2017.09.041","article-title":"A comparison study between lycobetaine-loaded nanoemulsion and liposome using nRGD as therapeutic adjuvant for lung cancer therapy","volume":"111","author":"Chen","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0465","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1208\/s12249-021-02177-6","article-title":"Vitamin E oil incorporated liposomal melphalan and simvastatin: approach to obtain improved physicochemical characteristics of hydrolysable melphalan and anticancer activity in combination with simvastatin against multiple myeloma","volume":"23","author":"Sambamoorthy","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.lfs.2024.122989_bb0470","doi-asserted-by":"crossref","unstructured":"Lin, Z., Chu, B., Qu, Y., Wei, X., Huang, J., Wang, F., Feng, Y., Wang, X., Luo, H., Zhai, X., Xu, J., Liu, X., Zhang, L., Chen, F., Wu, Y., & Zheng, Y. (2023, 2023\/01\/10). Liposome-encapsulated melphalan exhibits potent antimyeloma activity and reduced toxicity. ACS Omega, 8(1), 1693\u20131701. doi:https:\/\/doi.org\/10.1021\/acsomega.2c07555.","DOI":"10.1021\/acsomega.2c07555"},{"issue":"4","key":"10.1016\/j.lfs.2024.122989_bb0475","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.3747\/co.21.1798","article-title":"Bortezomib in multiple myeloma: systematic review and clinical considerations","volume":"21","author":"Kouroukis","year":"2014","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.lfs.2024.122989_bb0480","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0485","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.3390\/pharmaceutics15122674","article-title":"Optimized liposomal delivery of bortezomib for advancing treatment of multiple myeloma","volume":"15","author":"Zhang","year":"2023","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.lfs.2024.122989_bb0490","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000463","article-title":"Complete tumor regression by liposomal bortezomib in a humanized mouse model of multiple myeloma","volume":"4","author":"Deshantri","year":"2020","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0495","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3390\/cancers12061473","article-title":"BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma","volume":"12","author":"Cho","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2024.122989_bb0500","doi-asserted-by":"crossref","unstructured":"Federico, C., Alhallak, K., Sun, J., Duncan, K., Azab, F., Sudlow, G. P., de la Puente, P., Muz, B., Kapoor, V., Zhang, L., Yuan, F., Markovic, M., Kotsybar, J., Wasden, K., Guenthner, N., Gurley, S., King, J., Kohnen, D., Salama, N. N., Thotala, D., Hallahan, D. E., Vij, R., DiPersio, J. F., Achilefu, S., & Azab, A. K. (2020, 2020\/11\/27). Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nature Communications, 11(1), 6037. doi:https:\/\/doi.org\/10.1038\/s41467-020-19932-1.","DOI":"10.1038\/s41467-020-19932-1"},{"issue":"36","key":"10.1016\/j.lfs.2024.122989_bb0505","doi-asserted-by":"crossref","first-page":"60656","DOI":"10.18632\/oncotarget.19269","article-title":"Emerging drugs and combinations to treat multiple myeloma","volume":"8","author":"Larocca","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.lfs.2024.122989_bb0510","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/1872210515666210720125717","article-title":"Micelles in cancer therapy: an update on preclinical and clinical status","volume":"16","author":"Aqeel","year":"2022","journal-title":"Recent Pat. Nanotechnol."},{"key":"10.1016\/j.lfs.2024.122989_bb0515","doi-asserted-by":"crossref","unstructured":"Kaur, J., Gulati, M., Jha, N. K., Disouza, J., Patravale, V., Dua, K., & Singh, S. K. (2022, 2022\/05\/01\/). Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation. Drug Discov. Today, 27(5), 1495\u20131512. doi:https:\/\/doi.org\/10.1016\/j.drudis.2022.02.005.","DOI":"10.1016\/j.drudis.2022.02.005"},{"issue":"3","key":"10.1016\/j.lfs.2024.122989_bb0520","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jha2.709","article-title":"Selinexor: targeting a novel pathway in multiple myeloma","volume":"4","author":"Mo","year":"2023","journal-title":"EJHaem"},{"issue":"Supplement 1","key":"10.1016\/j.lfs.2024.122989_bb0525","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2022-166493","article-title":"Selinexor-loaded polymeric micelles for multiple myeloma therapy","volume":"140","author":"Yang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.122989_bb0530","doi-asserted-by":"crossref","unstructured":"Varela-Moreira, A., van Straten, D., van Leur, H. F., Ruiter, R. W. J., Deshantri, A. K., Hennink, W. E., Fens, M. H. A. M., Groen, R. W. J., & Schiffelers, R. M. (2020, 2020\/12\/01\/). Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model. Int. J. Pharm.: X, 2, 100049. doi:https:\/\/doi.org\/10.1016\/j.ijpx.2020.100049.","DOI":"10.1016\/j.ijpx.2020.100049"},{"key":"10.1016\/j.lfs.2024.122989_bb0535","doi-asserted-by":"crossref","unstructured":"Chen, R., Yang, J., Mao, Y., Zhao, X., Cheng, R., Deng, C., & Zhong, Z. (2023, 2023\/11\/13). Antibody-mediated nanodrug of proteasome inhibitor carfilzomib boosts the treatment of multiple myeloma. Biomacromolecules, 24(11), 5371\u20135380. doi:https:\/\/doi.org\/10.1021\/acs.biomac.3c00830.","DOI":"10.1021\/acs.biomac.3c00830"},{"key":"10.1016\/j.lfs.2024.122989_bb0540","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wang, X., Cheng, R., & Zhong, Z. (2020, 2020\/06\/08). A6 peptide-tagged core-disulfide-cross-linked micelles for targeted delivery of proteasome inhibitor carfilzomib to multiple myeloma in vivo. Biomacromolecules, 21(6), 2049\u20132059. doi:https:\/\/doi.org\/10.1021\/acs.biomac.9b01790.","DOI":"10.1021\/acs.biomac.9b01790"},{"key":"10.1016\/j.lfs.2024.122989_bb0545","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.2147\/CMAR.S255682","article-title":"Inhibition of multiple myeloma using 5-aza-2\u2032-deoxycytidine and bortezomib-loaded self-assembling nanoparticles","author":"Che","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lfs.2024.122989_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1024143","article-title":"Polymeric nanoparticles-promising carriers for cancer therapy","volume":"10","author":"Xiao","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"11","key":"10.1016\/j.lfs.2024.122989_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113144","article-title":"Recent advances in nanotherapeutics for multiple myeloma","volume":"12","author":"Iannazzo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.122989_bb0565","doi-asserted-by":"crossref","unstructured":"Gurunathan, S., Thangaraj, P., Wang, L., Cao, Q., & Kim, J.-H. (2024, 2024\/01\/01\/). Nanovaccines: an effective therapeutic approach for cancer therapy. Biomed. Pharmacother., 170, 115992. doi:https:\/\/doi.org\/10.1016\/j.biopha.2023.115992.","DOI":"10.1016\/j.biopha.2023.115992"},{"key":"10.1016\/j.lfs.2024.122989_bb0570","doi-asserted-by":"crossref","unstructured":"Sun, Z., Zhao, H., Ma, L., Shi, Y., Ji, M., Sun, X., Ma, D., Zhou, W., Huang, T., & Zhang, D. (2024, 2024\/02\/14). The quest for nanoparticle-powered vaccines in cancer immunotherapy. J. Nanobiotechnol., 22(1), 61. doi:https:\/\/doi.org\/10.1186\/s12951-024-02311-z.","DOI":"10.1186\/s12951-024-02311-z"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0575","doi-asserted-by":"crossref","first-page":"169","DOI":"10.20517\/cdr.2022.138","article-title":"Anti-BCMA novel therapies for multiple myeloma","volume":"6","author":"Sammartano","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.lfs.2024.122989_bb0580","doi-asserted-by":"crossref","unstructured":"Bae, J., Parayath, N., Ma, W., Amiji, M., Munshi, N., & Anderson, K. C. (2020, 2020\/01\/01). BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia, 34(1), 210\u2013223. doi:https:\/\/doi.org\/10.1038\/s41375-019-0540-7.","DOI":"10.1038\/s41375-019-0540-7"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0585","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41408-023-00955-y","article-title":"BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma","volume":"13","author":"Dutta","year":"2023","journal-title":"Blood Cancer J."},{"issue":"14","key":"10.1016\/j.lfs.2024.122989_bb0590","first-page":"4985","article-title":"CD38-selective immuno-nano-DM1 conjugates for depleting multiple myeloma. Biomaterials","volume":"11","author":"Yuan","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.lfs.2024.122989_bb0595","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1007\/s13204-021-02010-3","article-title":"Rationally engineered losmapimod encapsulating polymeric nanoparticles for treatment of human multiple myeloma cells","volume":"11","author":"Ye","year":"2021","journal-title":"Appl. Nanosci."},{"key":"10.1016\/j.lfs.2024.122989_bb0600","doi-asserted-by":"crossref","unstructured":"Zhu, D., Wang, Z., Zhao, J.-J., Calimeri, T., Meng, J., Hideshima, T., Fulciniti, M., Kang, Y., Ficarro, S. B., Tai, Y.-T., Hunter, Z., McMilin, D., Tong, H., Mitsiades, C. S., Wu, C. J., Treon, S. P., Dorfman, D. M., Pinkus, G., Munshi, N. C., Tassone, P., Marto, J. A., Anderson, K. C., & Carrasco, R. D. (2015, 2015\/06\/01). The Cyclophilin A\u2013CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat. Med., 21(6), 572\u2013580. doi:https:\/\/doi.org\/10.1038\/nm.3867.","DOI":"10.1038\/nm.3867"},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph13121182","article-title":"Recent advances on inorganic nanoparticle-based cancer therapeutic agents","volume":"13","author":"Wang","year":"2016","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.lfs.2024.122989_bb0610","doi-asserted-by":"crossref","unstructured":"Mishra, P. K., Mishra, H., Ekielski, A., Talegaonkar, S., & Vaidya, B. (2017, 2017\/12\/01\/). Zinc oxide nanoparticles: a promising nanomaterial for biomedical applications. Drug Discov. Today, 22(12), 1825\u20131834. doi:https:\/\/doi.org\/10.1016\/j.drudis.2017.08.006.","DOI":"10.1016\/j.drudis.2017.08.006"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0615","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22672-5","article-title":"In vitro and ex vivo anti-myeloma effects of nanocomposite As4S4\/ZnS\/Fe3O4","volume":"12","author":"Cholujova","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2024.122989_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122019","article-title":"Radiolabeling and cytotoxicity of monoclonal antibody Isatuximab functionalized silver nanoparticles on the growth of multiple myeloma","volume":"624","author":"El-Shershaby","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2024.122989_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.jallcom.2023.172986","article-title":"Bimetallic S. pachycarpa@ Ag-doped ZnO alloy nanoparticles unveil therapeutic promise: revolutionizing multiple myeloma treatment","volume":"975","author":"Siami-Aliabad","year":"2024","journal-title":"J. Alloys Compd."},{"key":"10.1016\/j.lfs.2024.122989_bb0630","series-title":"Handbook of Carbon Nanotubes","first-page":"1","article-title":"Carbon nanotubes for drug delivery applications","author":"Batra","year":"2020"},{"key":"10.1016\/j.lfs.2024.122989_bb0635","doi-asserted-by":"crossref","unstructured":"de Almeida Barcelos, K., Garg, J., Ferreira Soares, D. C., de Barros, A. L. B., Zhao, Y., & Alisaraie, L. (2023, 2023\/09\/01\/). Recent advances in the applications of CNT-based nanomaterials in pharmaceutical nanotechnology and biomedical engineering. Journal of Drug Delivery Science and Technology, 87, 104834. doi:https:\/\/doi.org\/10.1016\/j.jddst.2023.104834.","DOI":"10.1016\/j.jddst.2023.104834"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0640","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s11671-022-03707-2","article-title":"PEG@ carbon nanotubes composite as an effective nanocarrier of ixazomib for myeloma cancer therapy","volume":"17","author":"Elgamal","year":"2022","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.lfs.2024.122989_bb0645","doi-asserted-by":"crossref","unstructured":"Carvalho, G. C., S\u00e1bio, R. M., de C\u00e1ssia Ribeiro, T., Monteiro, A. S., Pereira, D. V., Ribeiro, S. J. L., & Chorilli, M. (2020, 2020\/09\/07). Highlights in mesoporous silica nanoparticles as a multifunctional controlled drug delivery nanoplatform for infectious diseases treatment. Pharm. Res., 37(10), 191. doi:https:\/\/doi.org\/10.1007\/s11095-020-02917-6.","DOI":"10.1007\/s11095-020-02917-6"},{"issue":"3","key":"10.1016\/j.lfs.2024.122989_bb0650","article-title":"Mesoporous silica nanoparticles: a","volume":"10","author":"Narayan","year":"2018","journal-title":"comprehensive review on synthesis and recent advances. Pharmaceutics"},{"key":"10.1016\/j.lfs.2024.122989_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.micromeso.2021.111320","article-title":"Biomimetic mesoporous vectors enabling the efficient inhibition of wild-type isocitrate dehydrogenase in multiple myeloma cells","volume":"325","author":"Cauda","year":"2021","journal-title":"Microporous Mesoporous Mater."},{"key":"10.1016\/j.lfs.2024.122989_bb0660","doi-asserted-by":"crossref","unstructured":"Faict, S., Muller, J., De Veirman, K., De Bruyne, E., Maes, K., Vrancken, L., Heusschen, R., De Raeve, H., Schots, R., Vanderkerken, K., Caers, J., & Menu, E. (2018, Nov 8). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J., 8(11), 105. doi:https:\/\/doi.org\/10.1038\/s41408-018-0139-7.","DOI":"10.1038\/s41408-018-0139-7"},{"issue":"23","key":"10.1016\/j.lfs.2024.122989_bb0665","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.2021014749","article-title":"Exosomes in multiple myeloma: from bench to bedside","volume":"140","author":"Menu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2024.122989_bb0670","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ceb.2014.05.004","article-title":"Biogenesis and secretion of exosomes","volume":"29","author":"Kowal","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"issue":"4","key":"10.1016\/j.lfs.2024.122989_bb0675","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J. Cell Biol."},{"issue":"7_Supplement","key":"10.1016\/j.lfs.2024.122989_bb0680","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1538-7445.AM2023-2004","article-title":"Abstract 2004: selective cytotoxicity of multiple myeloma using novel cell membrane lipid-extracted nanoliposomes","volume":"83","author":"Amorin","year":"2023","journal-title":"Cancer Res."},{"issue":"40","key":"10.1016\/j.lfs.2024.122989_bb0685","article-title":"Encapsulation of nano-bortezomib in apoptotic stem cell-derived vesicles for the treatment of multiple myeloma","volume":"19","author":"Cao","year":"2023","journal-title":"Small"},{"issue":"6","key":"10.1016\/j.lfs.2024.122989_bb0690","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/biom12060784","article-title":"Nano-based approved pharmaceuticals for cancer treatment: present and future challenges","volume":"12","author":"Rodr\u00edguez","year":"2022","journal-title":"Biomolecules"},{"issue":"17","key":"10.1016\/j.lfs.2024.122989_bb0695","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.2165\/0003495-200868170-00008","article-title":"Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma","volume":"68","author":"Plosker","year":"2008","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.lfs.2024.122989_bb0700","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"van der Meel","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"11","key":"10.1016\/j.lfs.2024.122989_bb0705","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3390\/nano10112186","article-title":"Understanding nanoparticle toxicity to direct a safe-by-design approach in cancer nanomedicine","volume":"10","author":"Damasco","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.lfs.2024.122989_bb0710","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0715","doi-asserted-by":"crossref","DOI":"10.3390\/biom14010083","article-title":"Harnessing nanotechnology: emerging strategies for multiple myeloma therapy","volume":"14","author":"Yang","year":"2024","journal-title":"Biomolecules"},{"issue":"15","key":"10.1016\/j.lfs.2024.122989_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/nano12152672","article-title":"Recent advances in nanoparticle-based co-delivery systems for cancer therapy","volume":"12","author":"Al Bostami","year":"2022","journal-title":"Nanomaterials (Basel)"},{"issue":"1","key":"10.1016\/j.lfs.2024.122989_bb0730","article-title":"Multifunctional nanoparticle for cancer therapy","volume":"4","author":"Gao","year":"2023","journal-title":"MedComm (2020)"},{"issue":"4","key":"10.1016\/j.lfs.2024.122989_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040267","article-title":"The microfluidic technique and the manufacturing of polysaccharide nanoparticles","volume":"10","author":"Chiesa","year":"2018","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.lfs.2024.122989_bb0740","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ame2.12165","article-title":"Cancer models in preclinical research: a chronicle review of advancement in effective cancer research","volume":"4","author":"Sajjad","year":"2021","journal-title":"Animal Model Exp Med"},{"issue":"12","key":"10.1016\/j.lfs.2024.122989_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14123006","article-title":"Patient derived ex-vivo cancer models in drug development, personalized medicine, and radiotherapy","volume":"14","author":"Zitter","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524005794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524005794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T02:17:57Z","timestamp":1726280277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524005794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":145,"alternative-id":["S0024320524005794"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122989","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"122989"}}